WisdomTree India Earnings Fund (EPI) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
ESSA Pharma Inc. reports steady progress in their clinical trials for treating prostate cancer, with key milestones expected in the upcoming months. They have a healthy cash runway to fund operations beyond 2025, and are on track to present significant trial data in the second half of 2024, including Phase 1 masofaniten plus enzalutamide dose escalation study results and Phase 1b monotherapy results.
For further insights into EPI stock, check out TipRanks’ Stock Analysis page.
